Portal vein embolization and its effect on tumour progression for colorectal cancer liver metastases

British Journal of Surgery

Volumn 102, Issue 10, 2015, Pages 1240-1249

  Simoneau, E ^a   Hassanain, M ^a,b   Shaheen, M ^a   Aljiffry, M ^c   Molla, N ^a   Chaudhury, P ^a   Anil, S ^b   Khashper, A ^a   Valenti, D ^a   Metrakos, P ^a  

^a MCGILL UNIVERSITY   (Canada)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c King Abdulaziz University   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CHEMOEMBOLIZATION; COLORECTAL NEOPLASMS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER NEOPLASMS; MALE; METASTASIS; MIDDLE AGED; PATHOLOGY; PORTAL VEIN; PREOPERATIVE CARE; PROCEDURES; RADIOGRAPHY; RETROSPECTIVE STUDY; SECONDARY; THREE DIMENSIONAL IMAGING; TREATMENT OUTCOME; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; CHEMOEMBOLIZATION, THERAPEUTIC; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; IMAGING, THREE-DIMENSIONAL; INFUSIONS, INTRAVENOUS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PORTAL VEIN; PREOPERATIVE CARE; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84939214119     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.9872     Document Type: Article

References (40)

1. Elias D, Debaere T, Roche A, Bonvallot S, Lasser P,. Preoperative selective portal vein embolizations are an effective means of extending the indications of major hepatectomy in the normal and injured liver. Hepatogastroenterology 1998; 45: 170-177.
2. Ribero D, Abdalla EK, Madoff DC, Donadon M, Loyer EM, Vauthey J-N,. Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. Br J Surg 2007; 94: 1386-1394.
3. Azoulay D, Castaing D, Smail A, Adam R, Cailliez V, Laurent A, et-al. Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization. Ann Surg 2000; 231: 480-486.
4. Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey J-N, Mahvi D,. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006; 13: 1271-1280.
5. Shindoh J, Tzeng CW, Aloia TA, Curley SA, Zimmitti G, Wei SH, et-al. Portal vein embolization improves rate of resection of extensive colorectal liver metastases without worsening survival. Br J Surg 2013; 100: 1777-1783.
6. Abulkhir A, Limongelli P, Healey AJ, Damrah O, Tait P, Jackson J, et-al. Preoperative portal vein embolization for major liver resection. Ann Surg 2008; 247: 49-57.
7. Farges O, Belghiti J, Kianmanesh R, Regimbeau JM, Santoro R, Vilgrain V, et-al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 2003; 237: 208-217.
8. Ardito F, Vellone M, Barbaro B, Grande G, Clemente G, Giovannini I, et-al. Right and extended-right hepatectomies for unilobar colorectal metastases: impact of portal vein embolization on long-term outcome and liver recurrence. Surgery 2013; 153: 801-810.
9. Mueller L, Hillert C, Möller L, Krupski-Berdien G, Rogiers X, Broering DC,. Major hepatectomy for colorectal metastases: is preoperative portal occlusion an oncological risk factor? Ann Surg Oncol 2008; 15: 1908-1917.
10. Kokudo N, Tada K, Seki M, Ohta H, Azekura K, Ueno M, et-al. Proliferative activity of intrahepatic colorectal metastases after preoperative hemihepatic portal vein embolization. Hepatology 2001; 34: 267-272.
11. Oussoultzoglou E, Bachellier P, Rosso E, Scurtu R, Lucescu I, Greget M, et-al. Right portal vein embolization before right hepatectomy for unilobar colorectal liver metastases reduces the intrahepatic recurrence rate. Ann Surg 2006; 244: 71-79.
12. Abdalla EK,. Portal vein embolization (prior to major hepatectomy) effects on regeneration, resectability, and outcome. J Surg Oncol 2010; 102: 960-967.
13. Hemming AW, Reed AI, Howard RJ, Fujita S, Hochwald SN, Caridi JG, et-al. Preoperative portal vein embolization for extended hepatectomy. Ann Surg 2003; 237: 686-691.
14. Elias D, De Baere T, Roche A, Ducreux M, Leclere J, Lasser P,. During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma. Br J Surg 1999; 86: 784-788.
15. Barbaro B, Di Stasi C, Nuzzo G, Vellone M, Giuliante F, Marano P,. Preoperative right portal vein embolization in patients with metastatic liver disease. Metastatic liver volumes after RPVE. Acta Radiol 2003; 44: 98-102.
16. Simoneau E, Aljiffry M, Salman A, Abualhassan N, Cabrera T, Valenti D, et-al. Portal vein embolization stimulates tumour growth in patients with colorectal cancer liver metastases. HPB (Oxford) 2012; 14: 461-468.
17. Hoekstra LT, van Lienden KP, Doets A, Busch ORC, Gouma DJ, van Gulik TM,. Tumor progression after preoperative portal vein embolization. Ann Surg 2012; 256: 812-187.
18. de Graaf W, van den Esschert JW, van Lienden KP, van Gulik TM,. Induction of tumor growth after preoperative portal vein embolization: is it a real problem? Ann Surg Oncol 2009; 16: 423-430.
19. Treska V, Skalicky T, Liska V, Sutnar A, Ferda J, Mirka H, et-al. Prognostic value of the number and volume of liver tumours on portal vein embolization outcomes. Hepatogastroenterology 2012; 59: 448-452.
20. Pamecha V, Levene A, Grillo F, Woodward N, Dhillon A, Davidson BR,. Effect of portal vein embolisation on the growth rate of colorectal liver metastases. Br J Cancer 2009; 100: 617-622.
21. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et-al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
22. Folprecht G, Gruenberger T, Bechstein WO, Raab H-R, Lordick F, Hartmann JT, et-al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 11: 38-47.
23. O'Reilly DA, Chaudhari M, Ballal M, Ghaneh P, Wu A, Poston GJ,. The Oncosurge strategy for the management of colorectal liver metastases-an external validation study. Eur J Surg Oncol 2008; 34: 538-540.
24. Beal IK, Anthony S, Papadopoulou A, Hutchins R, Fusai G, Begent R, et-al. Portal vein embolisation prior to hepatic resection for colorectal liver metastases and the effects of periprocedure chemotherapy. Br J Radiol 2006; 79: 473-478.
25. Sturesson C, Keussen I, Tranberg KG,. Prolonged chemotherapy impairs liver regeneration after portal vein occlusion-an audit of 26 patients. Eur J Surg Oncol 2010; 36: 358-364.
26. Reddy SK, Morse MA, Hurwitz HI, Bendell JC,. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 2008; 206: 96-106.
27. Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S, et-al. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 2008; 26: 5254-5260.
28. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et-al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 2013; 14: 1208-1215.
29. Ak G, Metintas M, Metintas S, Yildirim H, Ozkan R, Ozden H,. Three-dimensional evaluation of chemotherapy response in malignant pleural mesothelioma. Eur J Radiol 2010; 74: 130-135.
30. Jeon D-G, Kong C-B, Cho WH, Song WS, Cho SH, Choi SW, et-al. Examination of the cutoff value of postchemotherapy increase in tumor volume as a predictor of subsequent oncologic events in stage IIB osteosarcoma. J Surg Oncol 2014; 109: 275-279.
31. Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM,. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004; 240: 438-447.
32. Abdalla EK, Vauthey J-N, Ellis LM, Ellis V, Pollock R, Broglio KR, et-al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004; 239: 818-825.
33. Scheele J, Stangl R, Altendorf-Hofmann A,. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 1990; 77: 1241-1246.
34. Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, et-al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004; 240: 1052-1061.
35. Neumann UP, Thelen A, Röcken C, Seehofer D, Bahra M, Riess H, et-al. Nonresponse to pre-operative chemotherapy does not preclude long-term survival after liver resection in patients with colorectal liver metastases. Surgery 2009; 146: 52-59.
36. Pommier R, Ronot M, Cauchy F, Gaujoux S, Fuks D, Faivre S, et-al. Colorectal liver metastases growth in the embolized and non-embolized liver after portal vein embolization: influence of initial response to induction chemotherapy. Ann Surg Oncol 2014; 21: 3077-3083.
37. Pamecha V, Glantzounis G, Davies N, Fusai G, Sharma D, Davidson B,. Long-term survival and disease recurrence following portal vein embolisation prior to major hepatectomy for colorectal metastases. Ann Surg Oncol 2009; 16: 1202-1207.
38. Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL, et-al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008; 26: 3523-3529.
39. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et-al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
40. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, et-al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007; 25: 4779-4786.